Nucala 100 mg powder for solution for injection clinical trials

E-merge - Evaluation of MEpolizumab-based regimen Compared to Conventional Therapeutic Strategy For Remission Induction In Patients With Eosinophilic Granulomatosis With Polyangiitis. Prospective, randomized, controlled, double-blind study

This study is testing a new way to treat EGPA, a rare condition causing inflammation. It compares a new drug called mepolizumab to standard treatments to see if it can help patients reduce their steroid dose and avoid flare-ups.